328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
     
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Alzheimer's Cases to Double by 2060: ReportGene Discovery May Help Fight Alzheimer'sCould New 'Brain Training' Program Help Prevent Dementia?Millions Could Miss Out on a Potential Alzheimer's BreakthroughSleep Apnea May Boost Alzheimer's RiskNew Finding Hints at Clue to DementiaResilient Brain Connections May Help Against Alzheimer'sAmerica's Dementia Caregivers Cite Stresses, RewardsHealth Tip: Identifying Vascular DementiaOne Type of Dementia Is Especially CostlyA More Accurate Predictor for Alzheimer's?Failing Sense of Smell Tied to Dementia RiskIs Dementia Declining Among Older Americans?Intracranial Pressure Monitoring No Benefit in Pediatric TBIGender-Specific High-Risk 'Window' Seen in Alzheimer'sWomen at Risk for Alzheimer's Face Critical 10-Year Window, Study SaysDo Fewer Nightly Dreams Mean Higher Dementia Risk in Seniors?Dementia Care: A Huge Financial Burden for U.S. FamiliesPopular Heartburn Drugs Don't Raise Risk of Alzheimer's: StudyFamilies Shoulder Majority of Costs Related to Dementia CareMidlife Vascular Risk Factors Tied to Increased Risk of DementiaMidlife Behaviors May Affect Your Dementia RiskTraveling With Dementia: Tips for Family CaregiversHigher Risk of Dementia Seen in Those Hailing From 'Stroke Belt'Health Tip: Alzheimer's Affects SleepNoninvasive Brain Test May Pinpoint Type of DementiaTargeting 9 Risk Factors Could Prevent 1 in 3 Dementia Cases: StudyAAIC: Rx + Training Shows Benefit in Advanced Alzheimer'sAAIC: Alzheimer Biomarkers Up With Sleep Disordered BreathingDozens of Potential Alzheimer's Meds in the PipelineSpecial Training Plus Medication Might Help People With Advanced Alzheimer'sSleep Problems: An Early Warning Sign of Alzheimer's?PPIs Not Found to Raise Risk of Alzheimer's DiseasePopular Heartburn Meds Don't Raise Alzheimer's Risk: StudyLifestyle Changes Might Prevent or Slow DementiaSevere Headaches Plague Vets With Traumatic Brain InjuriesSticky Brain 'Plaques' Implicated in Alzheimer's Again'Making the Best of It': Families Face the Heavy Burden of Alzheimer'sCognitive Decline Linked to Visual Field VariabilityAlzheimer's Deaths Jump 55 Percent: CDCLife Expectancy Slighter Shorter With Parkinson's, DementiaLow Body Mass Index Not Risk Factor for Alzheimer's DiseaseWives, Daughters Shoulder Most of Alzheimer's Care BurdenGene Mutation May Speed Alzheimer's DeclineSilent Seizures May Contribute to Alzheimer's Pathology'Silent' Seizures Tied to Alzheimer's SymptomsPsychiatric Scars of Wartime Brain Injury May Linger for YearsMany Patients With Alzheimer's Disease Discontinue AChEIsAntipsychotic Medication Use Can Be Reduced in Dementia PatientsPast Psychiatric Disorders Do Not Raise Risk of Alzheimer's Disease
Links
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Many Patients With Alzheimer's Disease Discontinue AChEIs


HealthDay News
Updated: Apr 26th 2017

new article illustration

WEDNESDAY, April 26, 2017 (HealthDay News) -- Discontinuation of acetylcholinesterase inhibitors (AChEIs) for treatment of Alzheimer's disease is common, with adverse effects and cost cited as major factors, according to a study published recently in the Journal of the American Geriatrics Society.

Noll L. Campbell, Pharm.D., from the Purdue University School of Pharmacy in West Lafayette, Ind., and colleagues randomized 196 older adults with a diagnosis of possible or probable Alzheimer's disease who were initiating treatment with an AChEI to one of three AChEIs (1:1:1) for 18 weeks.

In the intent to treat analysis, the researchers found that discontinuation rates at the end of 18 weeks were 38.8 percent for donepezil, 53.0 percent for galantamine, and 58.7 percent for rivastigmine (P = 0.063). Adverse events explained 73.1 percent of discontinuation, while cost explained 25.4 percent. More than 81 percent of participants reported adverse events, but rates were similar between groups.

"This pragmatic comparative trial showed high rates of adverse events and cost-related nonadherence with AChEIs," the authors write.

Abstract
Full Text (subscription or payment may be required)




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net